Physician profile
Saima Husain
NPI 1427237007
$4,285.42
in general payments reported to CMS, 2019-2025
10 companies · $1,409 in 2025
The $1,409 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.03 · 2022: $13.89 · 2023: $996 · 2024: $1,844 · 2025: $1,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,087 · Food and Beverage: $1,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,087.10 |
| Food and Beverage | $1,161.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,603.72 | 2023-2024 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $1,100.40 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $235.29 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $222.14 | 2024-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $35.95 | 2022-2024 | Wainua |
| Merck Sharp & Dohme LLC | $25.98 | 2023 | Verquvo |
| Pfizer INC. | $18.99 | 2023 | |
| Novo Nordisk INC | $18.55 | 2024 | Wegovy |
| Boston Scientific Corporation | $13.29 | 2023 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saima Husain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.